Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTango Therapeutics announces two director resignations alongside Q1 2026 earnings release
Filed May 13, 2026 · Period ending May 13, 2026 · ~1 min read
Key Changes
-
medium
Lead Independent Director Alexis Borisy and director Kanishka Pothula both resigned from the Board effective May 13, 2026. The company stated neither resignation resulted from disagreements on operations, practices, or policies.
Item 5.02 verify on EDGAR → -
medium
Sung Lee was appointed as the new Lead Independent Director and Compensation Committee Chairperson, filling the leadership vacuum left by Borisy's departure.
Item 5.02 verify on EDGAR → -
medium
Tango issued its Q1 2026 financial results via press release on May 13, 2026. Actual financial figures are contained in the attached press release exhibit, not in the 8-K body.
Item 2.02 verify on EDGAR →
Summary
Tango Therapeutics disclosed two significant board changes coinciding with its first quarter 2026 earnings announcement. Alexis Borisy, who served as Lead Independent Director and Compensation Committee Chair, resigned along with fellow director Kanishka Pothula, both effective May 13, 2026. The company emphasized that neither departure stemmed from disagreements about company operations or strategy.
Sung Lee immediately stepped into Borisy's leadership roles, maintaining board continuity. For retail investors, simultaneous director departures—even when characterized as amicable—warrant attention, particularly when they involve the Lead Independent Director who oversees executive compensation. The timing alongside quarterly earnings may be coincidental but creates uncertainty about board dynamics. Watch for any additional director changes in coming months and monitor whether the company provides further context in its upcoming 10-Q filing or investor communications about board composition strategy.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 13, 2026, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended March 31, 2026.
Tango announced its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures; those are in the attached press release exhibit. This is a standard quarterly earnings disclosure filing.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026. Mr. Borisy’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.
Alexis Borisy resigned from the Board of Directors, relinquishing his roles as Lead Independent Director and Compensation Committee Chairperson, effective May 13, 2026. The company disclosed that his resignation was not due to any disagreement with the company on operations, practices, or policies.
Added in current filing · verify on EDGAR →
Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026. Mr. Pothula’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.
Kanishka Pothula resigned from the Board and the Nominating and Corporate Governance Committee, effective May 13, 2026. The company stated his resignation was not due to any disagreement with the company on operations, practices, or policies.
Added in current filing · verify on EDGAR →
In connection with Mr. Borisy’s and Mr. Pothula’s resignations from the Board, the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.
Sung Lee was appointed to replace Alexis Borisy as Lead Independent Director and Compensation Committee Chairperson, effective May 13, 2026. Lee was also appointed to the Nominating and Corporate Governance Committee to fill the vacancy left by Pothula's resignation.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Press Release issued by Tango Therapeutics, Inc. on May 13, 2026 relating to its results of operations and financial condition for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results via press release. The 8-K itself contains no financial details; the substantive disclosure is in the attached Exhibit 99.1 press release.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify